Literature DB >> 3546139

Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.

F Dromer, J Salamero, A Contrepois, C Carbon, P Yeni.   

Abstract

Two monoclonal immunoglobulin G1 antibodies reacting with Cryptococcus neoformans capsular polysaccharide (CNPS) were produced in mice by using a carefully defined procedure for immunization with unmodified CNPS purified from C. neoformans serotype A. Since the antibodies were found to have the same pattern of specificity, only one of them (E1) is described. This anti-CNPS monoclonal antibody reacted with the glucuronoxylomannan component of CNPS but not with the constituent monosaccharides or with the mannose alpha(1----3)-linked oligosaccharide structures present on CNPS. E1 appeared to be specific for C. neoformans serotype A by agglutination of whole cells; it was specific for soluble CNPS A by gel immunoprecipitation. However, indirect immunofluorescence and competitive-binding enzyme-linked immunosorbent assay experiments showed low levels of cross-reactivity with serotypes B and D but not with serotype C. Concentrations 10,000 times higher for serotypes B and D cells than for serotype A cells were required for a 50% inhibition of E1 anti-CNPS A activity as measured by enzyme-linked immunosorbent assay. Among the other yeasts tested, a cross-reaction was only detected with Trichosporon beigelii. The four serotypes of C. neoformans could be distinguished based on intensities and patterns of fluorescence in an indirect immunofluorescence assay using the monoclonal anti-CNPS A antibody. Monoclonal anti-CNPS A antibodies could be useful for fundamental studies on the glucuronoxylomannan structure, as well as for clinical applications such as serotyping and possibly the serological diagnosis of cryptococcosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3546139      PMCID: PMC260404          DOI: 10.1128/iai.55.3.742-748.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  CRYPTOCOCCUS NEOFORMANS POLYSACCHARIDE: STUDIES OF SEROLOGIC PROPERTIES AND ROLE IN INFECTION.

Authors:  J E BENNETT; H F HASENCLEVER
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

2.  Serology of human cryptococcosis.

Authors:  D D Bindschadler; J E Bennett
Journal:  Ann Intern Med       Date:  1968-07       Impact factor: 25.391

3.  The wide spectrum of cryptococcal infections.

Authors:  J L Lewis; S Rabinovich
Journal:  Am J Med       Date:  1972-09       Impact factor: 4.965

4.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

5.  Serologic grouping of Cryptococcus neoformans.

Authors:  D E Wilson; J E Bennett; J W Bailey
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

6.  Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.

Authors:  R Cherniak; E Reiss; M E Slodki; R D Plattner; S O Blumer
Journal:  Mol Immunol       Date:  1980-08       Impact factor: 4.407

Review 7.  Composition and structure of yeast cell walls.

Authors:  G H Fleet
Journal:  Curr Top Med Mycol       Date:  1985

8.  Production of specific antibody to Cryptococcus neoformans by hybridomas in vitro.

Authors:  N K Hall; R Blackstock
Journal:  Sabouraudia       Date:  1981-06

9.  Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

10.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more
  60 in total

1.  Laboratory techniques in the investigation of fungal infections.

Authors:  R J Hay
Journal:  Genitourin Med       Date:  1992-12

Review 2.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

3.  Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide.

Authors:  D L Goldman; S C Lee; A J Mednick; L Montella; A Casadevall
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.

Authors:  Marcio L Rodrigues; Leonardo Nimrichter; Débora L Oliveira; Susana Frases; Kildare Miranda; Oscar Zaragoza; Mauricio Alvarez; Antonio Nakouzi; Marta Feldmesser; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2006-11-17

5.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

6.  Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.

Authors:  Leonardo Nimrichter; Susana Frases; Leonardo P Cinelli; Nathan B Viana; Antonio Nakouzi; Luiz R Travassos; Arturo Casadevall; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2007-06-15

7.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

8.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Interference by hydroxyethyl starch used for vascular filling in latex agglutination test for cryptococcal antigen.

Authors:  L Millon; T Barale; M C Julliot; J Martinez; G Mantion
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

10.  The Eiken Latex test for detection of a cryptococcal antigen in cryptococcosis. Comparison with a monoclonal antibody-based latex agglutination test, Pastorex Cryptococcus.

Authors:  K Tanaka; S Kohno; T Miyazaki; H Miyazaki; K Mitsutake; S Maesaki; M Kaku; H Koga
Journal:  Mycopathologia       Date:  1994-09       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.